Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
MULTICENTER STUDY
Peter Bader, Hermann Kreyenberg, Arend von Stackelberg, Cornelia Eckert, Emilia Salzmann-Manrique, Roland Meisel, Ulrike Poetschger, Daniel Stachel, Martin Schrappe, Julia Alten, Andre Schrauder, Ansgar Schulz, Peter Lang, Ingo Müller, Michael H Albert, Andre M Willasch, Thomas E Klingebiel, Christina Peters
PURPOSE: To elucidate the impact of minimal residual disease (MRD) after allogeneic transplantation, the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster Stem Cell Transplantation Group (ALL-BFM-SCT) conducted a prospective clinical trial. PATIENTS AND METHODS: In the ALL-BFM-SCT 2003 trial, MRD was assessed in the bone marrow at days +30, +60, +90, +180, and +365 after transplantation in 113 patients with relapsed disease. Standardized quantification of MRD was performed according to the guidelines of the Euro-MRD Group...
April 10, 2015: Journal of Clinical Oncology
#2
EDITORIAL
Albert Oriol
No abstract text is available yet for this article.
2015: Acta Haematologica
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
